Ziarco Appoints David L. Brinkley to the Board of Directors
News Jul 25, 2013
His role at Ziarco will be to provide input on the company's corporate, R&D strategy and business plans.
Commenting on his appointment, Mr. Brinkley said: "Ziarco’s assets have strong potential to yield differentiated, important new medicines to address unmet needs of patients across a spectrum of disorders. I look forward to assisting in the growth and success of the company.”
Ziarco’s CEO, Dr Mike Yeadon, commented: "We are delighted that David has joined our board and is providing valuable advice to the team. His substantial experience in new product planning, development of new medicines and business partnering are good compliments to the deep scientific expertise within Ziarco. His insights will be invaluable to use as we drive our portfolio of preclinical and clinical programs forward."
Mr. Brinkley was Head of Business Development from November 2008 to July 2013 and had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007, when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc. leading the team that had full responsibility for the U.S. and subsequent global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham's Animal Health operations and was Director of new product planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline from 1983 to 1995. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018